Drug Trial Radar · NCT05642182
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
Last checked: Nov 19, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 31, 2022
Primary completion
Jul 30, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- SFA TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
Conditions
- Psoriasis
Interventions
SFA002Drug
Study drug formula without excipient
SFA002Drug
Study Drug SFA002 with excipient (Propionate)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Psoriasis Area and Severity Index (PASI) ScoreTime frame: From enrollment to final visit at 24 weeks treatment and 4 week follow-up
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NuLine Clinical Trial Center
Pompano Beach, Florida · Recruiting
Axis Clincals USA/ Red River Research Patners. LLC
Fargo, North Dakota · Recruiting
Temple University
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.